 |
|
|
|
January 2007 Cover
|
|
New Jersey-based Bristol-Myers Squibb said the Food and Drug Administration has approved its single-capsule formulation of Reyataz as part of combination therapy for HIV infection. The approval means the
300-milligram capsule eliminates the need to take two 150-milligram capsules. Reyataz is meant to be used in combination with ritonavir.
Editor's Note: from the Associated Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
